Sudo Bio

   /   About   /   Team

Leaders committed to life-changing therapeutics

Sudo Biosciences leadership brings deep expertise to small molecule development in neurological and immune-mediated inflammatory conditions.

Jump to:

Sudo Team Board of Directors Investors

Sudo Team

Scott Byrd

Chief Executive Officer

Ian Mills, BM, BCh, DM

Chief Medical Officer

Gordon McMurray, PhD

Chief Development Officer

Imran Babar, PhD

Chief Business & Financial Officer

Anjali Pandey, PhD

SVP, Medicinal Chemistry

David Hennings, PhD

SVP, CMC

Alessio Alfieri, PhD

Neurodegeneration

Vassilios Aslanis, PharmD, MSc, PhD(c)

Head of Clinical Pharmacology

Rachel Eccles, PhD

Head of Translational Pharmacology

Mark Evans, PhD

Neuropharmacology

Sally Fillingham

Clinical Trial Administration

Royston Gray

Head of Non-Clinical Development

Sarah Loughrey-Jennings

Clinical Trial Management

Kelly Munro, PhD

Clinical Pharmacology

Matt Nelan, FCCA

Finance

Peadar O’Donohoe, MBChB DPhil

Head of Clinical Development

Waylon Parham, CPA

Controller, Finance

Kejal Patel

Head of Clinical Operations

Fenella Smith

Executive Assistant

Gerry Thomas, PhD

R&D Project Management

Terrie Walker-Smith

Clinical Trial Management

Board of Directors

Scott Byrd

Director

Edd Fleming, MD

Director

Shinichiro Fuse, PhD

Director

Chris Gagliardi, PhD

Director

Dave Johnson

Director

Dan Estes, PhD

Director

Investors

Partners in life science innovation